A 35-year-old man with moderate persistent asthma (daytime symptoms 4 days/week, nighttime symptoms 2 nights/week) is currently on inhaled salbutamol as needed. He has had 2 exacerbations in the past year requiring oral corticosteroids. His baseline FEV₁ is 72% of predicted. He is adherent to therapy and has no comorbidities. What is the most appropriate next step in his asthma management?

Explanation

## Stepwise Asthma Management: Step 3 Therapy **Key Point:** This patient has **moderate persistent asthma** with inadequate control on SABA alone. According to GINA and NAEPP guidelines, patients with persistent asthma (any frequency of daytime or nighttime symptoms) require **daily maintenance therapy**. The presence of 2 exacerbations in 1 year confirms inadequate control. ### Asthma Control Classification | Parameter | Intermittent | Mild Persistent | Moderate Persistent | Severe Persistent | |-----------|--------------|-----------------|----------------------|-----------------| | Daytime symptoms | ≤2 days/week | 3–4 days/week | >4 days/week or daily | Throughout the day | | Nighttime symptoms | ≤2 nights/month | 3–4 nights/month | >1 night/week but not nightly | 7 nights/week (nightly) | | FEV₁ | ≥95% | 80–95% | 60–79% | <60% | | Exacerbations/year | 0–1 | ≥2 | ≥2 | ≥2 | | **Recommended therapy** | SABA PRN | ICS monotherapy (Step 2) | ICS-LABA (Step 3) | ICS-LABA ± LTRA ± LAMA (Step 4–5) | **This patient:** Daytime symptoms 4 days/week + nighttime symptoms 2 nights/week + 2 exacerbations/year + FEV₁ 72% = **Moderate Persistent = Step 3** ### GINA Stepwise Treatment Algorithm ```mermaid flowchart TD A[Asthma diagnosis confirmed]:::outcome --> B{Assess control}:::decision B -->|Intermittent| C[Step 1: SABA PRN only]:::action B -->|Mild persistent| D[Step 2: ICS monotherapy daily]:::action B -->|Moderate persistent| E[Step 3: ICS-LABA combination daily]:::action B -->|Severe persistent| F[Step 4-5: ICS-LABA + LTRA/LAMA]:::action E --> G[Reassess in 4 weeks]:::decision G -->|Controlled| H[Continue Step 3]:::outcome G -->|Uncontrolled| I[Step up to Step 4]:::action E --> J[SABA still available for acute symptoms]:::action ``` **High-Yield:** ICS-LABA combination is **superior to ICS monotherapy** in moderate-to-severe asthma because: 1. LABA provides sustained bronchodilation (12 hours). 2. ICS provides anti-inflammatory control. 3. Combination reduces exacerbation rate by ~50% compared to ICS alone [cite:GINA 2023]. **Clinical Pearl:** The **ICS-LABA should be prescribed as a single inhaler** (e.g., fluticasone-salmeterol, budesonide-formoterol, mometasone-formoterol). This ensures the patient takes both drugs together, improving adherence and efficacy. **Mnemonic: STEP-UP** (Symptoms Trigger Escalation; Persistent asthma requires Upward Progression) - **S**ABA alone → Intermittent only - **T**herapy escalation → Persistent symptoms = daily maintenance - **E**very step adds or upgrades drugs - **P**ersistent mild → ICS monotherapy (Step 2) - **U**pgrade to ICS-LABA → Moderate persistent (Step 3) - **P**rogression → Step 4–5 if uncontrolled ### Why ICS-LABA, Not ICS Monotherapy? - **ICS alone** (Step 2) is for **mild persistent** asthma (symptoms 3–4 days/week). - This patient has **moderate persistent** asthma (symptoms >4 days/week or nightly, plus 2 exacerbations/year). - ICS-LABA provides superior control and reduces exacerbations in moderate-to-severe asthma. ### Dosing Example - **Fluticasone-salmeterol:** 125/25 mcg or 250/25 mcg, 2 inhalations twice daily. - **Budesonide-formoterol:** 80/4.5 mcg or 160/4.5 mcg, 2 inhalations twice daily. - Continue SABA (salbutamol) as rescue therapy for acute symptoms. **Warning:** LABA monotherapy without ICS is contraindicated—it increases asthma mortality. Always use ICS-LABA combination, never LABA alone.